PE75099A1 - HIV PROTEASE INHIBITOR - Google Patents

HIV PROTEASE INHIBITOR

Info

Publication number
PE75099A1
PE75099A1 PE1998000432A PE00043298A PE75099A1 PE 75099 A1 PE75099 A1 PE 75099A1 PE 1998000432 A PE1998000432 A PE 1998000432A PE 00043298 A PE00043298 A PE 00043298A PE 75099 A1 PE75099 A1 PE 75099A1
Authority
PE
Peru
Prior art keywords
hiv protease
crystalline
refers
compound
protease inhibitor
Prior art date
Application number
PE1998000432A
Other languages
Spanish (es)
Inventor
Richard J Varsolona
David Askin
Robert M Purick
Ralph P Volante
Paul Reider
R Scott Hoerrner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714320.0A external-priority patent/GB9714320D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE75099A1 publication Critical patent/PE75099A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), CRISTALINO O SU MONOETANOLATO, HEMIETANOLATO, SESQUIETANOLATO CRISTALINO; CARACTERIZADO POR SU CURVA DE BARRIDO DIFERENCIAL DE CALORIMETRIA (DSC); PATRON DE DIFRACCION DEL POLVO A LOS RAYOS X. TAMBIEN SE REFIERE AL PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I EN FORMA DE SAL DE SULFATO INHIBE LA PROTEASA DEL VIH POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO O PREVENIR LA INFECCION POR VIH MOSTRANDO UNA MAYOR SOLUBILIDAD EN HCl DILUIDO, ASI COMO UNA ABSORCION ORAL Y BIODISPONIBILIDAD MEJORADAREFERS TO A COMPOUND OF FORMULA (I), CRYSTALLINE OR ITS MONOETHANOLATE, HEMIETHANOLATE, CRYSTALLINE SQUIETHANOLATE; CHARACTERIZED BY ITS DIFFERENTIAL SWEEPING CALORIMETRY CURVE (DSC); DIFFERENCE PATTERN OF DUST TO X-RAYS. ALSO REFERS TO THE PREPARATION PROCEDURE. COMPOUND I IN THE FORM OF SULPHATE SALT INHIBITS HIV PROTEASE SO IT CAN BE USEFUL FOR TREATMENT OR PREVENT HIV INFECTION BY SHOWING MORE SOLUBILITY IN DILUTED HCl, AS WELL AS ORAL ABSORPTION AND BIOAVAILABILITY

PE1998000432A 1997-05-29 1998-05-28 HIV PROTEASE INHIBITOR PE75099A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4795097P 1997-05-29 1997-05-29
GBGB9714320.0A GB9714320D0 (en) 1997-07-07 1997-07-07 Hiv protease inhibitor

Publications (1)

Publication Number Publication Date
PE75099A1 true PE75099A1 (en) 1999-08-11

Family

ID=26311845

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000432A PE75099A1 (en) 1997-05-29 1998-05-28 HIV PROTEASE INHIBITOR

Country Status (22)

Country Link
EP (1) EP0986554A1 (en)
JP (1) JP3267632B2 (en)
KR (1) KR20010013042A (en)
CN (1) CN1257497A (en)
AU (1) AU730245B2 (en)
BG (1) BG103923A (en)
BR (1) BR9809498A (en)
CA (1) CA2291086A1 (en)
EA (1) EA199901095A1 (en)
EE (1) EE9900543A (en)
HR (1) HRP980283A2 (en)
HU (1) HUP0004621A3 (en)
ID (1) ID23858A (en)
IL (1) IL132779A0 (en)
IS (1) IS5240A (en)
NO (1) NO995822L (en)
PE (1) PE75099A1 (en)
PL (1) PL336847A1 (en)
SK (1) SK163299A3 (en)
TR (1) TR199902816T2 (en)
TW (1) TW438799B (en)
WO (1) WO1998054178A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514910A (en) * 1999-11-24 2003-04-22 メルク エンド カムパニー インコーポレーテッド Gamma-hydroxy-2- (fluoroalkylaminocarbonyl) -1-piperazinepentanamides as HIV protease inhibitors
WO2002022582A2 (en) * 2000-09-14 2002-03-21 Ortho-Mcneil Pharmaceutical, Inc. Solid salt forms of n-[2-[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]ethyl]-2-oxo-1-piperidineacetamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ278201A (en) * 1993-12-15 1998-01-26 Merck & Co Inc Bicyclic heterocyclically substituted piperazine derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
WO1998054178A1 (en) 1998-12-03
KR20010013042A (en) 2001-02-26
BG103923A (en) 2000-06-30
HRP980283A2 (en) 1999-08-31
IL132779A0 (en) 2001-03-19
NO995822D0 (en) 1999-11-26
HUP0004621A2 (en) 2002-03-28
NO995822L (en) 2000-01-28
SK163299A3 (en) 2000-07-11
AU7595998A (en) 1998-12-30
EE9900543A (en) 2000-06-15
EA199901095A1 (en) 2000-08-28
PL336847A1 (en) 2000-07-17
CN1257497A (en) 2000-06-21
TW438799B (en) 2001-06-07
BR9809498A (en) 2000-06-20
ID23858A (en) 2000-05-25
CA2291086A1 (en) 1998-12-03
TR199902816T2 (en) 2000-02-21
EP0986554A1 (en) 2000-03-22
JP2000513747A (en) 2000-10-17
HUP0004621A3 (en) 2002-04-29
IS5240A (en) 1999-11-09
JP3267632B2 (en) 2002-03-18
AU730245B2 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
AR112669A2 (en) INHIBITING COMPOUNDS OF SODIUM AND GLUCOSE 2 CARRIER AND USEFUL COMPOUNDS FOR THEIR PREPARATION
BR0307267A (en) Heterocyclic compounds, active as inhibitors of beta-lactams
MX9403380A (en) HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS.
PE20110388A1 (en) CRYSTALLINE FORMS OF A PEPTIDE DERIVATIVE AS HCV INHIBITORS
CY1108559T1 (en) SALTS of Valsartan
BR0212477A (en) 7-aza [2.2.1] Substituted bicycloheptanes for the treatment of disease
SV2008002969A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
ATE478841T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, THE AZETIDINE DERIVATIVES AND THE PRODUCTION THEREOF
ES2191977T3 (en) SOLUTIONS AND DISPERSIONS IN SOLID STATE OF PHARMACOS LITTLE SOLUBLES IN WATER.
UY26872A1 (en) DERIVATIVES OF THE 4- PIRIDINE PHENYL
ECSP044992A (en) INHIBITORS OF THE ALQUÍN-ARIL FOSFODIESTERASA-4
AR034985A1 (en) BICYCLE COMPOUND; PRODUCTION AND USE OF THE SAME
TR200400238T4 (en) Alpha crystalline form of the perindopril tert-butylamine salt
BR9908470A (en) Compound, pharmaceutical composition, and process to treat conditions mediated by avb3 inegrin in a mammal in need of such treatment
NO20052907D0 (en) Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferative agents.
ES2192101T3 (en) CRYSTAL FORMS OF ETO2C-CH2- (R) CGL-AZE-PAB-OH.
AR031940A1 (en) HERBICIDE AGENT
BR0101230A (en) Process for the preparation of 11-amino-3-chloro-6,11-dihydro-5-5-dioxo-6-methyl-dibenzo [c, f] [1,2] thiazepine and application for the synthesis of detianeptine
UY27980A1 (en) INDOLES 2,7-REPLACED
UY27577A1 (en) HIV INTEGRAS INHIBITORS
CO5570696A2 (en) 1-AMINO-ALQUILCICLOHEXANOS INSATURATED AS ANTAGONISTS OF NMDA, 5HT3 AND NEURONAL NICOTINIC RECEPTORS
PE75099A1 (en) HIV PROTEASE INHIBITOR
BRPI0406704A (en) 5ht ~ 7 ~ Antagonists and Inverse Agonists
ATE308540T1 (en) ANTITHROMBOTIC AGENTS

Legal Events

Date Code Title Description
FD Application declared void or lapsed